Doctors Express Concerns about Participating in Jamboree Competition for Global Youths

"Doctors express concerns about participating in Jamboree competition for global youths - 'There will be casualties if we proceed as Is' Medical teams from Jeonbuk, including the Korean Medical Association and hospitals, were dispatched to provide medical support, but the on-site medical assistance situation remains inadequate. [관련기사=잼버리대회 참여한 세계 청소년들 걱정하는 의사들 "이대로 강행하면 희생자 나온다"] [MedigateNews] Amidst the World Scout Jamboree, which is taking place in SaeManGeum, Jeonbuk's Buan County, from the

Leclaza approved as first-line treatment

[관련기사 = 렉라자 1차치료제 승인 이유? "L858R 변이·뇌전이·아시안·한국인에서 효능 강점"] "Strengths in L858R mutation · brain metastases · Asians and Koreans " Yuhan Corporation’s Leclaza tab(ingredient: Lazertinib) was recently approved by the Ministry of Food and Drug Safety as a first-line treatment for epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer. The basis for this expansion of approval is the phase 3 clinical trial of LASER301. The LASER301 clinical trial was done in 96 institution

Dong-A ST Blockbuster NASH, obesity treatment in development

[관련 기사 = 동아ST 블록버스터 가능성 주목…경구용 NASH·식욕억제+운동효과 비만주사 개발 중] Kim Mi-Kyung Head of a R&D department says "Obesity drug with oral NASH and appetite suppressant + exercise effect at the same time" Mi-Kyung Kim, head of the Dong-A ST Research Headquarters' Immune Disease Research Division, said in an interview that the company will commercialize DA-1241, a new drug candidate for an oral NASH treatment, and DA-1726, an obesity treatment injection candidate, by 2030. In 2011, Dong-A ST developed DA-1241 a

GE Healthcare worker dies after being crushed by CT table while repairing equipment at hospital

Gettyimage GE Healthcare worker dies after being crushed by CT table while repairing equipment at hospital The Ministry of Employment and Labor investigates on the potential violation against Serious Accident Punishment Act of the company...Emergency of hospital and medical equipment industry [관련기사=GE헬스케어 직원, 병원서 장비 수리 중 CT테이블에 깔려 숨져] [MedigateNews] It is known that an accident occurred in which a GE Healthcare Korea employee was crushed by a CT table while checking a computed tomography (CT) sc

IlDong Pharmaceutical's Unprecedented Large-Scale Restructuring

[관련 기사 = 1분기 실적 엇갈린 명암…일동제약 이례적인 대규모 구조조정] Mixed Results for Mid-Sized Pharmaceutical Companies in the First Quarter... IlDong Pharmaceutical's Unprecedented Large-Scale Restructuring Boryung Seeks New Business Expansion with Strong Growth Momentum, including Aerospace Medicine... SK Bioscience Expands R&D despite Losses due to the ending of Pandemic There is a growing focus on IlDong Pharmaceutical, a domestic mid-sized pharmaceutical company, as it embarks on intense management transformation

'Preventing the disclosure of doctors' identities in the event of expenditure report

Kang Han-cheol, Attorney at Law, from Kim & Chang. [관련 기사 = "의사 실명공개 반대…합법적 경제적이익도 '불법 리베이트' 인식 가능"] "Preventing the disclosure of doctors' identities in the event of expenditure report disclosure and strengthening supervision of CSOs" Both the pharmaceutical industry and the medical and legal sectors have expressed concerns about defamation, loss of trust in doctors, and the activation of illicit rebates. With the impending implementation of the expenditure report disclosure system, criticisms

The second digital therapeutic device for improving insomnia in Korea, 'WELT-I,' developed by WELT

[관련기사 = 국내 두 번째 디지털치료기기도 불면증 개선…웰트 'WELT-I'] The second digital therapeutic device for improving insomnia in Korea, 'WELT-I,' developed by WELT Based on the data entered by the patient, the device improves the patient's insomnia over a period of 6 weeks. The second digital therapeutic device (DTx) in South Korea is also dedicated to treating insomnia. The Ministry of Food and Drug Safety (MFDS) approved the manufacturing license for cognitive therapy software (product name: WELT-I) developed by

SK Bioscience announces "Investment of 2.4 trillion won over the next 5 years despite negative growth"

[관련 기사 = SK바이오사이언스 "향후 5년 집중 투자 시기…마이너스 성장에도 미래를 위한 길"] SK Bioscience announces "Investment of 2.4 trillion won over the next 5 years despite negative growth" Jae-yong Ahn, CEO of SK Bioscience, unveils plans to boost global competitiveness During a recent press conference, Jae-yong Ahn, SK Bioscience CEO expressed “He determine to pursue concentrated investments over the next five years to secure global competitiveness, despite the rapid changes in business environment due to the endemic.” SK B

Daewoong Pharmaceutical Launches Envlo, Its First Domestic SGLT-2 Inhibitor Medication.

Domestic new drug No. 36 has demonstrated superior blood sugar lowering effects and safety with a low dosage of 0.3mg. [관련기사 = 대웅제약, 국내 첫 SGLT-2 억제제 신약 '엔블로정' 출시 동시에 보험급여 적용] Daewoong Pharmaceutical has succeeded in localizing a SGLT-2 inhibitor drug for the treatment of diabetes, becoming the first domestic pharmaceutical company to do so. The company announced on May 1 that its new drug, Envlo, has been approved for insurance coverage and will be officially launched in Korea. Envlo is available in a 0.3mg dose (ingredient name: enavogliflozin) and has been approved for three indications: monotherapy, combinati

Where have the medical doctors gone in the last 10 years? The medical practitioner is on the rise by 13,000.

Getty Images [관련기사=10년간 의사들 어디로 갔나 봤더니…개원의사 '1만3000명' 증가] Patients are flocking to the big hospitals, while doctors are soaring to clinic-level medical institutions. The number of doctors in hospitals and convalescent hospitals is on the decline. The medical treatment-related organization that has been chosen by most medical doctors for the past ten years was a clinic-level medical institution. The number of medical doctors who work in clinic-level medical institutions has increased by 4.1%p ove